Jun 2026 (Q2 FY26) — Aug 4, 2026
Strata Critical Medical Q2 FY26 — Strong Clinical Growth and Accelerated Capital Deployment
Read the full callStrata Critical Medical (SRTA) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Strata Critical Medical earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 72.5 | +60.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -7.5 | +2.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -10.5 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$4.54 0.00% · $0
Performance −9.0% 1Y
1Y: $4.99 on 17 Oct 2025 → $4.54. High $6.47 (28 May 2026), low $4.03 (20 Nov 2025).
- Previous close
- $4.54
- 52-week range
- $4.03 – $6.47
- One year
- −12.86%
Overview
- Symbol
- SRTA
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Strata Critical Medical earnings calls (SRTA)
Financials
What the filings say
Net profit, year on year: −181% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 36 | 54 | 36 | 45 | 49 | 67 | 67 | 73 |
| Expenses | 43 | 63 | 62 | 76 | 55 | — | — | — |
| Operating profit | -7 | -8 | -6 | -5 | -6 | -6 | -3 | -5 |
| Operating margin | −19.7% | −15.4% | −15.8% | −10.3% | −11.4% | −9.6% | −4.4% | −7.5% |
| Other income | 1 | -2 | 4 | 1 | -4 | 1 | 5 | -5 |
| Profit before tax | -6 | -10 | -2 | -3 | -10 | -5 | 2 | -11 |
| Tax rate | 0.0% | 1.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net profit | -2 | -10 | -3 | -4 | 57 | -9 | 2 | -11 |
| EPS ($ per share) | -0.03 | — | -0.04 | -0.05 | 0.70 | — | 0.03 | -0.12 |
| Line item | Dec 2019 | Sep 2020 | Dec 2020 | Sep 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | — | 0 | — | 0 | 0 | 0 | 0 | 0 |
| Reserves | 2 | -37 | -18 | -77 | -104 | -160 | -187 | -146 |
| Total liabilities | 26 | 7 | 47 | 52 | 51 | 61 | 35 | 46 |
| Fixed assets | — | 2 | — | 2 | 2 | 3 | 28 | 36 |
| Total assets | 278 | 18 | 278 | 343 | 325 | 295 | 257 | 325 |
| Line item | Sep 2019 | Sep 2020 | Dec 2020 | Sep 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -10 | -11 | -1 | -16 | -37 | -32 | -3 | -49 |
| Cash from investing | -1 | -0 | 0 | -321 | 79 | 17 | -1 | 70 |
| Cash from financing | 0 | 1 | — | 332 | -1 | -0 | -6 | -9 |
| Net cash flow | -11 | -10 | -0 | -5 | 41 | -15 | -9 | 12 |
| Capital expenditure | -1 | -0 | — | -0 | -1 | -2 | -31 | -10 |
| Free cash flow | -11 | -11 | — | -16 | -38 | -34 | -33 | -59 |
Insider filings
69 filings between Oct 22, 2025 and Sep 24, 2026.
Open market
decisions to buy or sellPurchases
$97.9K
2 purchases by 2 insiders
Sales
$507.0K
6 sales by 2 insiders
50% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 28
- Award — granted as compensation
- 3
- Option exercise — converted options into shares
- 30
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Cohen Amir | — | $382.3K | May 22, 2026 |
| Love Reginald | — | $124.8K | Aug 10, 2026 |
| Heyburn William A. | $76.0K | — | Dec 9, 2025 |
| LAUCK ANDREW | $21.8K | — | Dec 5, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 24, 2026 | Heyburn William A. Co-CEO and CFO | Award | 177,858 | $0 |
| Sep 24, 2026 | Tomkiel Melissa M. Co-CEO and General Counsel | Award | 177,858 | $0 |
| Sep 24, 2026 | Heyburn William A. Co-CEO and CFO | Tax withheld | 98,356 | $518.3K |
| Sep 24, 2026 | Tomkiel Melissa M. Co-CEO and General Counsel | Tax withheld | 90,797 | $478.5K |
| Sep 8, 2026 | Wunsch Scott M CEO, Logistics | Tax withheld | 5,711 | $30.3K |
| Sep 8, 2026 | Cohen Amir Chief Accounting Officer | Tax withheld | 4,645 | $24.7K |
| Sep 8, 2026 | Heyburn William A. Co-CEO and CFO | Tax withheld | 31,671 | $168.2K |
| Sep 8, 2026 | Tomkiel Melissa M. Co-CEO and General Counsel | Tax withheld | 29,730 | $157.9K |
| Sep 8, 2026 | Verdetto Louis R. CEO, Clinical Services | Tax withheld | 5,697 | $30.3K |
| Aug 10, 2026 | Love Reginald Director | Sale | 5,091 | $29.3K |
| Jul 31, 2026 | Tomkiel Melissa M. Co-CEO and General Counsel | Tax withheld | 212,309 | $1.08M |
| Jul 31, 2026 | Wunsch Scott M CEO, Logistics | Tax withheld | 13,992 | $71.2K |
| Jul 31, 2026 | Cohen Amir Chief Accounting Officer | Tax withheld | 34,015 | $173.1K |
| Jul 31, 2026 | Heyburn William A. Co-CEO and CFO | Tax withheld | 199,209 | $1.01M |
| Jul 30, 2026 | PHILIP EDWARD M Director | Award | 30,913 | $0 |
| Jul 30, 2026 | WIESENTHAL ROBERT S Director | Award | 50,234 | $0 |
| Jul 30, 2026 | LAUCK ANDREW Director | Award | 35,260 | $0 |
| Jul 30, 2026 | Tomkiel Melissa M. Co-CEO and General Counsel | Award | 206,953 | $0 |
| Jul 30, 2026 | Cohen Amir Chief Accounting Officer | Award | 27,420 | $0 |
| Jul 30, 2026 | Wunsch Scott M CEO, Logistics | Award | 57,172 | $0 |
| Jul 30, 2026 | Heyburn William A. Co-CEO and CFO | Award | 181,071 | $0 |
| Jul 30, 2026 | Tomkiel Melissa M. Co-CEO and General Counsel | Award | 208,929 | $0 |
| Jul 30, 2026 | Heyburn William A. Co-CEO and CFO | Award | 179,160 | $0 |
| Jul 30, 2026 | Cook William L. III Director | Award | 44,438 | $0 |
| Jul 30, 2026 | Love Reginald Director | Award | 37,675 | $0 |
| Jul 30, 2026 | Cohen Amir Chief Accounting Officer | Award | 41,786 | $0 |
| Jun 8, 2026 | Cohen Amir Chief Accounting Officer | Tax withheld | 4,655 | $27.3K |
| Jun 8, 2026 | Tomkiel Melissa M. Co-CEO and General Counsel | Tax withheld | 29,730 | $174.5K |
| Jun 8, 2026 | Heyburn William A. Co-CEO and CFO | Tax withheld | 31,671 | $185.9K |
| Jun 8, 2026 | Wunsch Scott M CEO, Logistics | Tax withheld | 5,550 | $32.6K |
| May 22, 2026 | Cohen Amir Chief Accounting Officer | Sale 10b5-1 plan | 40,575 | $239.8K |
| May 21, 2026 | Cohen Amir Chief Accounting Officer | Sale 10b5-1 plan | 10,300 | $59.6K |
| May 11, 2026 | Cohen Amir Chief Accounting Officer | Sale 10b5-1 plan | 14,306 | $82.8K |
| Apr 24, 2026 | Cohen Amir Chief Accounting Officer | Tax withheld | 40,960 | $201.5K |
| Apr 24, 2026 | Tomkiel Melissa M. Co-CEO and General Counsel | Tax withheld | 321,750 | $1.58M |
| Apr 24, 2026 | Heyburn William A. Co-CEO and CFO | Tax withheld | 301,731 | $1.48M |
| Apr 24, 2026 | Wunsch Scott M CEO, Logistics | Tax withheld | 13,922 | $68.5K |
| Apr 23, 2026 | Wunsch Scott M CEO, Logistics | Award | 57,172 | $0 |
| Apr 23, 2026 | Cohen Amir Chief Accounting Officer | Award | 83,505 | $0 |
| Apr 23, 2026 | Tomkiel Melissa M. Co-CEO and General Counsel | Award | 630,264 | $0 |
| Apr 23, 2026 | Heyburn William A. Co-CEO and CFO | Award | 545,625 | $0 |
| Mar 16, 2026 | Wunsch Scott M CEO, Trinity Air Medical | Award | 18,067 | $0 |
| Mar 8, 2026 | Wunsch Scott M CEO, Trinity Air Medical | Tax withheld | 3,631 | $16.5K |
| Mar 8, 2026 | Cohen Amir Chief Accounting Officer | Tax withheld | 2,433 | $11.0K |
| Mar 8, 2026 | Tomkiel Melissa M. Co-CEO and General Counsel | Tax withheld | 29,372 | $133.3K |
| Mar 8, 2026 | Heyburn William A. Co-CEO and CFO | Tax withheld | 31,314 | $142.2K |
| Feb 24, 2026 | Cohen Amir Chief Accounting Officer | Award | 64,191 | $0 |
| Feb 24, 2026 | Wunsch Scott M CEO, Trinity Air Medical | Award | 51,353 | $0 |
| Jan 2, 2026 | Tomkiel Melissa M. Co-CEO and General Counsel | Option exercise | 276,960 | $49.9K |
| Dec 10, 2025 | Tomkiel Melissa M. Co-CEO and General Counsel | Tax withheld | 34,018 | $149.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Strata Critical Medical, Inc.
Free account. Everything above stays public.
Write why you follow Strata Critical Medical, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading